Abstract
Rocuronium, a non-depolarizing neuromuscular blocking drug has a rapid onset of action, a comparatively low potency and, with a more favourable side effects profile than succinylcholine, it has become a popular alternative to that drug for rapid sequence inductions in anaesthesia. The rocuronium-binding cyclodextrin derivative sugammadex, prepared by per-6 substitution of the primary hydroxyls of γ-cyclodextrin with thiol ether-linked propionic acid side chains to extend the hydrophobic cavity to accommodate rocuronium, is used to reverse neuromuscular blockade by encapsulating the drug as an inclusion complex and removing it from the neuromuscular junction to the plasma. It has recently been suggested that sugammadex might also be of value in the management of rocuronium-induced anaphylaxis and this has been potentially supported by recent case reports. However, before sugammadex can be recommended for this purpose, it is important to establish whether or not the allergenic substituted ammonium groups at each end of the rocuronium molecule in the inclusion complex are masked within the cavity or left exposed for interaction with rocuronium-reactive IgE antibodies in the sera of rocuronium-allergic patients. Detailed experimental strategies and experimental protocols to investigate the allergenic potential of the sugammadex-rocuronium inclusion complex are presented and a possible explanation of the apparently rapid and successful reversal of anaphylaxis by administration of sugammadex is advanced and discussed.
Keywords: Sugammadex, perioperative anaphylaxis, cyclodextrins, drug allergy, rocuronium, drug-specific IgE.
Mini-Reviews in Medicinal Chemistry
Title:The Cyclodextrin Sugammadex and Anaphylaxis to Rocuronium: Is Rocuronium Still Potentially Allergenic in the Inclusion Complex Form?
Volume: 12 Issue: 8
Author(s): B. A. Baldo, N. J. McDonnell and N. H. Pham
Affiliation:
Keywords: Sugammadex, perioperative anaphylaxis, cyclodextrins, drug allergy, rocuronium, drug-specific IgE.
Abstract: Rocuronium, a non-depolarizing neuromuscular blocking drug has a rapid onset of action, a comparatively low potency and, with a more favourable side effects profile than succinylcholine, it has become a popular alternative to that drug for rapid sequence inductions in anaesthesia. The rocuronium-binding cyclodextrin derivative sugammadex, prepared by per-6 substitution of the primary hydroxyls of γ-cyclodextrin with thiol ether-linked propionic acid side chains to extend the hydrophobic cavity to accommodate rocuronium, is used to reverse neuromuscular blockade by encapsulating the drug as an inclusion complex and removing it from the neuromuscular junction to the plasma. It has recently been suggested that sugammadex might also be of value in the management of rocuronium-induced anaphylaxis and this has been potentially supported by recent case reports. However, before sugammadex can be recommended for this purpose, it is important to establish whether or not the allergenic substituted ammonium groups at each end of the rocuronium molecule in the inclusion complex are masked within the cavity or left exposed for interaction with rocuronium-reactive IgE antibodies in the sera of rocuronium-allergic patients. Detailed experimental strategies and experimental protocols to investigate the allergenic potential of the sugammadex-rocuronium inclusion complex are presented and a possible explanation of the apparently rapid and successful reversal of anaphylaxis by administration of sugammadex is advanced and discussed.
Export Options
About this article
Cite this article as:
A. Baldo B., J. McDonnell N. and H. Pham N., The Cyclodextrin Sugammadex and Anaphylaxis to Rocuronium: Is Rocuronium Still Potentially Allergenic in the Inclusion Complex Form?, Mini-Reviews in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/138955712801264828
DOI https://dx.doi.org/10.2174/138955712801264828 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Brain Perfusion In Sepsis
Current Vascular Pharmacology Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Current Cardiology Reviews Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews MicroRNAs and Ischemic Heart Disease: Towards a Better Comprehension of Pathogenesis, New Diagnostic Tools and New Therapeutic Targets
Recent Patents on Cardiovascular Drug Discovery Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Lappaconitine: Influence of Halogen Substituent on the Antiarrhythmic Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Insights into the Pervasive Role of M3 Muscarinic Receptor in Cardiac Diseases
Current Drug Targets Transforming Growth Factor-β (TGF-β ) and its Role in the Pathogenesis of Systemic Sclerosis: A Novel Target for Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Atrial Fibrillation During or After TAVI: Incidence, Implications and Therapeutical Considerations
Current Pharmaceutical Design Clinical PET Imaging of Insulinoma and Beta-Cell Hyperplasia
Current Pharmaceutical Design Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design